Page results
-
Exhibition co-curated by Healthcare Arts Collective and UCLH Arts and Heritage 25th August - 20th October 2021, UCH Street Gallery, 235 Euston Road
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
This page is for patients receiving steroids for immunotherapy toxicity.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
File results
-
FOI/2024/0263 - Longest wait for ophthalmology pathway treatment
-
FOI/2024/0268 - Module on imaging offered to PAs as training in requesting ionising radiation
-
FOI/2024/0269 - Paediatric audiology services
-
FOI/2024/0273 - Covid restrictions for visitors at Elizabeth Garret Anderson (EGA) from December 2021-June 2022
-
FOI/2024/0274 - Number of endoscopes at Trust
-
FOI/2024/0277 - Paediatric respiratory admission rates 2018-2023
-
FOI/2024/0279 - Social media management platforms and tools
-
FOI/2024/0283 - Cyber security/ cyber attack
-
FOI/2024/0285 - Private patient non-contractual tariffs
-
FOI/2024/0288 - Maternity ward closure for new admissions 2019-2023